Praeruptorin A Modulates STAT-1/3 to Alleviate Ulcerative Colitis in Mice

Study Background and Research Question

• Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease characterized by diffuse mucosal inflammation and ulceration of the colon, with increasing incidence worldwide, particularly in urbanized populations.
• Current first-line treatments—such as aminosalicylates, corticosteroids, immunosuppressants, and biologics—are often limited by incomplete efficacy, high relapse rates, and significant adverse effects, motivating exploration of alternative or adjunctive therapies.
• Natural products with multi-targeted anti-inflammatory activities are of growing interest, especially compounds capable of modulating epithelial barrier integrity, inflammatory signaling, and cytokine balance.
• The research question addressed by this study is whether Praeruptorin A (PA), an angular pyranocoumarin compound derived from Peucedanum praeruptorum Dunn, exerts protective effects against experimentally induced UC, and if so, through which molecular mechanisms.

Key Innovation from the Reference Study

• This work provides the first comprehensive in vivo and in vitro evidence that Praeruptorin A can alleviate acute ulcerative colitis symptoms in a dextran sulfate sodium (DSS)-induced mouse model.
• The study identifies inhibition of STAT-1 and STAT-3 phosphorylation as the central mechanistic axis underlying PA's anti-inflammatory and barrier-stabilizing actions.
• Through integration of network pharmacology and molecular docking, the study maps out additional potential targets and pathways, supporting a multi-modal therapeutic profile for this angular pyranocoumarin compound.

Methods and Experimental Design Insights

• Animal Model: Acute colitis was induced in mice using DSS, a well-established model recapitulating key histopathological and immunological features of human UC.
• Praeruptorin A Administration: PA was administered to DSS-exposed mice at doses compatible with established safety and efficacy parameters, as described in the reference study.
• Cell Culture Model: Human Caco-2 colonic epithelial cells were used to model barrier dysfunction and inflammatory signaling in vitro, enabling mechanistic validation at the cellular level.
• Readouts: Clinical symptoms, body weight, colon length, histopathology, apoptosis assays, tight junction protein expression, and cytokine levels were assessed. STAT-1/3 phosphorylation was measured by western blotting, and the effects of a STAT-1/3 inhibitor (AG490) were compared to those of PA.
• Bioinformatics: Network pharmacology and molecular docking analyses were performed to predict interacting targets and clarify pathway engagement.

Protocol Parameters

• PA dosing in vivo (mouse model): Literature-backed doses include 0.8–1.2 mg/kg/day intraperitoneally or 30 mg/kg/day via intragastric administration for 7 days, aligning with the product information.
• PA application in cell models: Effective in vitro concentrations range from 0.4 μM to 30 μM, depending on cell type and assay endpoint.
• DSS-induced colitis: 2–3% DSS in drinking water for 5–7 days is typical for acute model induction; PA is usually started simultaneously or as a pretreatment.

Core Findings and Why They Matter

• Symptom Relief: PA-treated mice exhibited significant reductions in body weight loss, diarrhea, rectal bleeding, and histological signs of mucosal damage compared to DSS-only controls (reference).
• Inflammatory Cytokine Suppression: PA markedly reduced colonic expression of pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β), while increasing anti-inflammatory mediators such as IL-10 and TGF-β. This cytokine shift is consistent with PA's role as an anti-inflammatory agent for ulcerative colitis.
• Barrier Function Restoration: PA upregulated tight junction proteins (ZO-1, occludin, claudin-1), reduced epithelial apoptosis, and restored mucosal architecture, pointing to direct protection of the intestinal barrier.
• STAT-1/3 Inhibition: PA suppressed phosphorylation (activation) of STAT-1 and STAT-3 in colonic tissue and Caco-2 cells. The similar efficacy of AG490, a known STAT-1/3 inhibitor, further supports this pathway as central to PA’s effect.
• Multi-targeted Potential: Network pharmacology and molecular docking indicate that PA may interact with additional targets relevant to inflammation and barrier integrity, underscoring its promise as a multi-mechanism therapeutic candidate.

Collectively, these findings suggest that Praeruptorin A not only dampens inflammatory signaling but also actively repairs and protects the colonic epithelial barrier, a dual action highly desirable in UC intervention strategies.

Comparison with Existing Internal Articles

• Praeruptorin A: Mechanistic Mastery and Strategic Guidance reviews the broad molecular mechanisms of Praeruptorin A, highlighting its role as a DMT1 and NF-κB pathway inhibitor in inflammation and cancer models. The current study builds on this by confirming STAT-1/3 as an additional, pivotal axis in UC.
• Molecular Precision in Ferroptosis and Inflammation Research outlines PA’s ferroptosis-inhibiting properties and general anti-inflammatory actions. The reference paper provides a disease-focused counterpart, applying these mechanistic insights directly to UC and epithelial barrier restoration.
• Optimizing Cell-Based Assays with Praeruptorin A details practical lab strategies, dose ranges, and solubility, complementing the reference study’s in vitro workflow and supporting researchers in assay design.

Limitations and Transferability

• These findings are based on acute DSS-induced colitis in mice and Caco-2 cell models; chronic UC, patient-derived tissues, and human trials may yield additional insights into efficacy and safety.
• The study does not fully dissect off-target or long-term effects, and the multi-pathway actions of Praeruptorin A warrant further specificity profiling.
• While the STAT-1/3 axis is pivotal in this context, PA’s impacts on other signaling pathways (e.g., NF-κB, ERK1/2) should be further explored in disease-relevant settings, as supported by related internal articles.
• Transferability to other inflammatory or autoimmune disease models requires direct experimental validation.

Research Support Resources

Researchers interested in probing the anti-inflammatory, barrier-protective, or multi-pathway actions of Praeruptorin A can access detailed workflow strategies and optimized protocols in the above-cited internal literature. For direct experimental work, Praeruptorin A (SKU N2885) is available from APExBIO, with validated dose ranges, solubility data, and handling guidance suitable for both in vitro and in vivo UC models. Its documented safety profile and mechanistic breadth make it a versatile tool for translational inflammation and epithelial barrier research.